NSE · LOTUSEYE
Lotus Eye Hospital & Institute Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹55 Cr with net profit ₹0 Cr — a 0.15% net margin, versus 1.45% the period before.
Shareholding
As of 2026-06-30
- Promoter40.14%
- Public59.85%
- DII0.02%
9,627 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.51× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Medical Care Facilities · ranked #3 of 3 by market cap · medians across 2 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Indraprastha Medical Corporation Ltd. | ₹3,256 Cr | 17.32 | 4.4 | 24.8% | 12.34% |
| GPT Healthcare Limited | ₹1,311 Cr | 27.73 | 4.86 | 15.67% | 9.61% |
| Lotus Eye Hospital & Institute Ltd.(this company) | ₹235 Cr | 1412.38 | 3.91 | 0.13% | 0.26% |
AI analysis
AI-generated · google/gemini-2.5-flashLotus Eye Hospital & Institute Ltd. is listed with a market capitalization of Rs 253 Cr. The company reported revenue of Rs 50.86 Cr and an EPS of Rs 0.04. The debt-to-equity ratio stands at 0.04.
Positives
- +The company's debt-to-equity ratio is low at 0.04.
- +Return on equity (ROE) is 13.4% as of the latest annual data.
Negatives
- −Promoter pledging is high, with 87.15% of promoter shares pledged as of June 30, 2026.
- −The company recorded a net loss of Rs -0.32 Cr in the quarter ending March 2026.
- −The company is under LT-ASM surveillance, indicating regulatory attention.
- −The price-to-earnings (P/E) ratio is high at 194.17.
- −Return on Capital Employed (ROCE) is low at 1.0589%.
Financial performance
For the financial year ending March 2025, revenue was Rs 50.86 Cr, with a net profit of Rs 0.7393 Cr. This follows a revenue of Rs 49.5126 Cr and a net profit of Rs 2.9145 Cr in March 2024. Quarterly revenue for March 2026 was Rs 13.61 Cr, resulting in a net loss of Rs -0.32 Cr.
Profitability & returns
The company recorded a profit margin of 14.9%. Return on equity (ROE) was 13.4%, and return on capital employed (ROCE) was 1.0589%. The earnings per share (EPS) for the latest available annual period was Rs 0.04.
Balance sheet
Lotus Eye Hospital & Institute Ltd. has a low debt-to-equity ratio of 0.04. The book value per share is Rs 28.92. There are no dividend payouts reported, with the dividend yield at 0%.
Ownership & pledges
As of June 30, 2026, promoter holding was 40.1373%, with public shareholding at 59.8471%. DIIs held 0.0156% of shares, with no FII holding. A significant portion of promoter shares, 87.15%, is pledged. The number of shareholders was 9627.
Regulatory & surveillance
The company is currently under LT-ASM surveillance, specifically ASM Stage 1. This includes measures such as LT-ASM.
Data as of — price: 2026-09-11 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Lotus Eye Hospital & Institute Ltd.share price & fundamentals